CBT Advisors CEO Steve Dickman has worked in consulting and venture capital for twenty years. He founded CBT Advisors in 2003 and has worked on storytelling and strategy with more than three hundred private biotechnology and life sciences clients. Much of the firm’s work focuses on drafting business sections for NASDAQ IPOs. Forty-three clients have gone public, raising $3.4 billion. IPO clients have included CRISPR Therapeutics, Karuna Therapeutics, Alector Inc., Black Diamond Therapeutics and others. Previously, Steve was a venture capitalist with TVM Capital, where his investments included Sirna Therapeutics, which was acquired in 2006 by Merck for $1.1 billion, and bluebird bio, which went public on Nasdaq (BLUE) in 2013. Steve publishes from time to time on Forbes.com.